.Charles Baum, M.D., Ph.D., who supervised Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squibb in 2014, is taking the reins of youthful biotech Terremoto Biosciences.Baum's "comprehensive adventure in medicine progression, and effective performance history earlier high-impact medicines, will be instrumental," outward bound CEO Peter Thompson, M.D., said in a July 25 launch. Thompson will keep his chair as board chairperson..Baum, a competent physician-scientist, was actually the founder, president and CEO of oncology-focused Mirati. Before that, he aided build cancer medicines at Pfizer and Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Right now, Baum will certainly act as CEO at Terremoto, a provider developing small molecules to target disease-causing healthy proteins-- like those located in harmful cyst cells-- making use of covalent connects. Existing therapies that utilize covalent bonds predominantly target the amino acid cysteine. Nevertheless, of the 20 amino acids that comprise proteins, cysteine is actually the minimum common. Terremoto is rather targeting some of the necessary amino acids, lysine, which is actually found in mostly all proteins.By targeting amino acid lysine as well as various other amino acids, Terremoto plans to treat formerly undruggable diseases and also produce first-in-class medicines..The biotech, located in South San Francisco, raised $75 million in collection A backing in 2022. A little much more than a year eventually, the biotech greater than multiplied that amount in a $175 thousand series B.